Abstract: The role of epicardial adipose tissue (EAT) in the pathophysiology of coronary artery disease (CAD) remains unclear. The present systematic review aimed at compiling dysregulated proteins/genes from different studies to dissect the potential role of EAT in CAD pathophysiology. Exhaustive literature research was performed using the keywords “epicardial adipose tissue and coronary artery disease”, to highlight a group of proteins that were consistently regulated among all studies. Reactome, a pathway analysis database, was used to clarify the function of the selected proteins and their intertwined association. SignalP/SecretomeP was used to clarify the endocrine function of the selected proteins. Overall, 1886 proteins/genes were identified from 44 eligible studies. The proteins were separated according to the control used in each study (EAT non-CAD or subcutaneous adipose tissue (SAT) CAD) and by their regulation (up- or downregulated). Using a Venn diagram, we selected the proteins that were upregulated and downregulated (identified as 27 and 19, respectively) in EAT CAD for both comparisons. The analysis of these proteins revealed the main pathways altered in the EAT and how they could communicate with the heart, potentially contributing to CAD development. In summary, in this study, the identified dysregulated proteins highlight the importance of inflammatory processes to modulate the local environment and the progression of CAD, by cellular and metabolic adaptations of epicardial fat that facilitate the formation and progression of atherogenesis of coronaries.

Keywords: coronary artery disease; epicardial adipose tissue; inflammation; cytokines

1. Introduction

The ever-growing health and socioeconomic burden related to obesity have gathered efforts aimed at revealing the complex association between adipose tissue and cardiovascular disease [1]. Interest in organ-specific adiposity is rapidly increasing as a substantial amount of scientific-based evidence suggests that adipose tissue anatomic specificity is crucial to the pathophysiology of cardiometabolic and endocrine diseases [2]. In this context, epicardial adipose tissue (EAT) has emerged as an exciting fat depot due to its location, peculiar metabolic properties, and clinical measurability [3]. Indeed, several studies have recognized EAT to be an independent predictor of coronary artery disease (CAD) [4,5]; however, the nature of this association remains to be clarified. Thus, this study aims to analyze the current literature focusing on the molecular signature of EAT derived from CAD patients. Our goal is to provide an overview of the potential impact of dysfunctional EAT on CAD pathophysiology.
1.1. Coronary Artery Disease

CAD is one of the most common forms of heart disease and a serious health problem worldwide. CAD can lead to myocardial ischemia, myocardial infarction, heart failure, and ultimately to death. CAD is a severe chronic disease, characterized by progressive atherosclerotic occlusion of the coronary arteries, resulting in a mismatch between myocardial oxygen demand and supply [6]. Atherosclerosis is described as a low-grade inflammatory state of the intima of medium-sized arteries that is accelerated by well-known risk factors such as hypertension, diabetes, obesity, and dyslipidemia [7]. In most observational studies, overweight/obesity has been associated with an increased prevalence of CAD, suggesting that it is the major risk factor associated with the pathophysiology and progression of the disease [8].

Moreover, the risk of developing CAD is not the same for individuals with the same percentage of body fat, which is mainly caused by the different distributions of fat. Patients with visceral obesity develop CAD quickly, demonstrating that this fat pad can predict CAD onset [9]. Figure 1 illustrates an overview of atherosclerosis pathophysiology and progression in CAD. More information can be consulted elsewhere [10,11].

![Figure 1](image1.png)

**Figure 1.** Coronary artery disease progression. LDL, low-density lipoproteins; HDL, high-density lipoproteins; SMC, smooth muscle cells. The figure was produced using Servier Medical Art.

1.2. Obesity as a Risk Factor for Coronary Artery Disease

Obesity is a worldwide epidemic, representing a public health concern. Obesity is determined by a body mass index (BMI) above 30 kg/m² [12]. However, it is widely known that BMI is a weak measurement of body fat, being influenced by muscle mass, body water content, and other factors. Furthermore, the relative contribution and burden of central, total, or subcutaneous adiposity to cardiovascular diseases needs further clarification. In lean subjects, subcutaneous adipose tissue (SAT) represents approximately 80% of the total adipose tissue mass, while visceral adipose tissue constitutes 15%. In obese patients, the percentage of visceral adipose tissue increases significantly, representing the most active fat subtype, which secretes adipocytokines that contribute to a systemic proinflammatory state and promote the development of cardiovascular atherosclerosis [13]. Moreover, visceral fat has the highest risk of metabolic dysregulation as a consequence of obesity, type II diabetes mellitus, or insulin resistance [14].

1.3. Epicardial Adipose Tissue

EAT is the fat depot that confers mechanical protection to the heart. It is directly connected to the myocardium, without any separating fascia, and shares the same circulation and blood supply [3]. EAT displays metabolic, thermogenic, and mechanical properties, with the higher rates of lipogenesis and fatty acid metabolism as compared to other fat subtypes. This enrichment and increased metabolism of free fatty acids (FFA) can be functionally important because the heart mostly depends on FFA
oxidation as a source of energy [3]. Moreover, as an endocrine organ, EAT is the source of several bioactive adipocytokines that can either protect or adversely affect the myocardium and coronary arteries. Under normal physiological conditions, EAT can trigger cardioprotective actions through paracrine or vasocrine secretion of anti-inflammatory adipocytokines, such as adiponectin. However, upon adipocytes dysfunction, the balance of epicardial fat secretome is disrupted, the production and secretion of protective adipocytokines declines, while the release of proinflammatory adipocytokines through epicardial adipocytes increases [3].

1.4. Epicardial Adipose Tissue and Coronary Artery Disease (CAD)

Currently, several imaging techniques are used to effectively quantify epicardial fat, such as magnetic resonance imaging, transthoracic echocardiography, and cardiac computed tomography [15]. Several populational studies have extensively described the predictive and associative impact of the thickness/volume of epicardial fat on the development and progression of CAD [3,16]. An increasing number of studies has shown that EAT volume was consistently associated with visceral obesity and metabolic syndrome, and potentially represented a marker of CAD in asymptomatic high-risk patients [17,18]. Consequently, the interest in studying EAT volume as a predictor of CAD has increased, demonstrating that it can be a useful marker of CAD in asymptomatic patients with noncalcified plaques and zero calcium scores. Interestingly, EAT significantly correlates with CAD development, independently of the existence of cardiovascular risk factors or the volume of other fat depots [19]. Accordingly, EAT volume correlated with coronary calcification independently of global and visceral abdominal adiposities in a cohort of stable elderly patients [20], supporting the idea that EAT could be involved in all stages of CAD.

Some studies have favored the idea that EAT facilitated coronary atherosclerosis directly through an imbalance between cardioprotective and deleterious adipocytokines secreted. These studies strongly supported adipocytokines paracrine rather than systemic effects [14]. Additionally, EAT from CAD patients have shown more interaction and adherence between cells and cell-to-matrix, an increased inflammatory response through the infiltration of complement factors and platelets, as well as dysfunction of lipid metabolism and mitochondria [21].

2. Methods

2.1. Search Strategy

Records that were published up to December 2019 were retrieved from the PubMed database. The keywords “epicardial adipose tissue” were combined with “coronary artery disease” for the search. Two authors (G.C. and D.M.) independently screened records, compared the results, and discussed discrepancies to obtain consensus at each step based on the criteria of study selection.

2.2. Inclusion and Exclusion Criteria of Study Selection

Studies conducted in CAD patients that performed molecular studies in EAT were included. Case reports, conference/dissertation abstracts, echocardiographic and clinic studies, animal model studies, literature reviews, and in vitro experiments were excluded.

2.3. Data Extraction

Data from the reports were manually curated and organized to extract all genes and proteins that could be identified and whose variation had been assessed between the different conditions. Only studies that reported significant differences ($p < 0.05$) were included. We separated the studies based on the control used (SAT) from CAD patients and EAT from non-CAD patients). The genes/proteins identified were separated by their regulation (up- or downregulated) as compared with a selected control. This resulted in four different lists of proteins/genes, namely: (a) the proteins/genes upregulated in EAT CAD as compared with EAT non-CAD, (b) the proteins
downregulated in EAT CAD as compared with EAT non-CAD, (c) the proteins upregulated in EAT CAD as compared with SAT CAD, and (d) the proteins downregulated in EAT CAD as compared with SAT CAD.

2.4. Bioinformatic Analysis

The identified genes and proteins were analyzed using the following bioinformatics tools: (1) PANTHER database (http://www.pantherdb.org) was used to perform gene ontology (GO) analyses, based on the biological process; (2) FunRich tool (http://www.funrich.org) was used to construct Venn diagrams, to perform an integrative analysis of the proteins/genes between the different groups; (3) SignalP and SecretomeP bioinformatics analysis were performed to search for putative secreted proteins [22] to elucidate the endocrine function of EAT in CAD, i.e., SignalP predicts classically secreted proteins based on signal peptide triggered protein secretion and SecretomeP predicts non-classical secreted proteins; and (4) Reactome, an open-source, peer-reviewed pathway analysis database [23], was used to clarify the relevance and to further explore the function of the proteins and their intertwined associations (http://reactome.org.). The set of selected genes from the Venn diagram and SignalP/SecretomeP analysis were placed into the “analysis” section of reactome. The program matches these proteins/genes to pathways and provides a pictogram of significant pathways (see Figure S1). The Reactome analysis program lists entities found in each pathway, along with a ratio of those genes found versus total molecules in the pathway, with a p value signifying “overrepresentation”, i.e., a larger number than would be expected if the set were random, with a Benjamin–Hochberg correction. Only the top 10 entities in the upregulated and the downregulated groups were detailed. The list also includes a false discovery rate (FDR) for each entity, indicating the expected proportion of rejected genes that were incorrect rejections.

3. Results

Over 571 abstracts were retrieved and reviewed, taking into account the exclusion and inclusion criteria, achieving 44 valid reports for further analysis (Figure 2). In a total of 44 studies, the average of participants ranged from 45 to 74 years. Mostly, EAT samples were collected adjacent to the right coronary artery to perform molecular studies, such as polymerase chain reaction (PCR), Western blot, and other methods. The characteristics for each paper analyzed and a list of the proteins identified can be found in Table S1.

From these 44 eligible studies, 1886 proteins/genes were identified as dysregulated in EAT and subjected to bioinformatic analysis to filter the most relevant information, as summarized in Figure 3. From these, 1108 were identified from studies with SAT CAD as the control and 778 were recognized from studies EAT CAD versus EAT non-CAD (Table S2). Figure 4A,B illustrates the expression pattern of each one of these comparisons. From all proteins identified in EAT as compared with EAT from non-CAD patients, 301 proteins were described as upregulated and 417 proteins as downregulated. Contrarily, 30 proteins were inconsistently regulated. Relative to EAT proteins with SAT CAD as the control, 635 proteins were upregulated and 393 proteins were downregulated, and 40 proteins were inconsistently regulated.

For further understanding of the different proteins differentially identified, the proteins were queried in the PANTHER database v15.0 and annotated GO terms based on biological processes. The classification results are illustrated in Figure 4C,D. Independent of the group used as the control, the 3 main biological processes in EAT CAD with more proteins were metabolic process (GO:0008152, \( p = 6.10 \times 10^{-29} \) vs. EAT non-CAD and \( p = 1.83 \times 10^{-12} \) vs. SAT CAD), cellular process (GO:0009987, \( p = 2.93 \times 10^{-28} \) vs. EAT non-CAD and \( p = 9.99 \times 10^{-16} \) vs. SAT CAD), and biological regulation (GO:0065007, \( p = 4.12 \times 10^{-19} \) vs. EAT non-CAD and \( p = 6.13 \times 10^{-29} \) vs. SAT CAD). In addition, response to stimulus (GO:0050896, \( p = 1.55 \times 10^{-57} \) vs. EAT non-CAD and \( p = 4.90 \times 10^{-37} \) vs. SAT CAD), cellular component organization or biogenesis (GO:0071840, \( p = 4.56 \times 10^{-8} \) vs. EAT non-CAD and \( p = 1.41 \times 10^{-6} \) vs. SAT CAD), localization (GO:0051179, \( p = 1.79 \times 10^{-21} \) vs. EAT non-CAD and
Int. J. Mol. Sci. 2020, 21, 8866

$p = 6.71 \times 10^{-21}$ vs. SAT CAD), signaling (GO:0023052, $p = 4.48 \times 10^{-28}$ vs. EAT non-CAD and $p = 3.43 \times 10^{-26}$ vs. SAT CAD), developmental process (GO:0032502, $p = 6.85 \times 10^{-6}$ vs. EAT non-CAD and $p = 4.18 \times 10^{-36}$ vs. SAT CAD), multicellular organismal process (GO:0032501, $p = 2.3 \times 10^{-16}$ vs. EAT non-CAD and $p = 1.46 \times 10^{-38}$ vs. SAT CAD), and immune system process (GO:0002376, $p = 3.73 \times 10^{-29}$ vs. EAT non-CAD and $p = 1.25 \times 10^{-27}$ SAT CAD) were also consistently highlighted.

A Venn diagram representing the differences in protein expression among groups was designed to highlight the most significant proteins underlying the interaction between EAT and CAD (Figure 5 and Table S3). This diagram identifies which proteins were simultaneously upregulated (27 in Figure 5, upregulated subgroup) and simultaneously downregulated (19 in Figure 5, downregulated subgroup) in EAT CAD for both comparisons (Table 1). On the one hand, from the upregulated proteins, one should highlight tumor necrosis factor, C-C motif chemokine 2, C-C motif chemokine 5, and interleukin (IL)-18. On the other hand, from the downregulated proteins, galectin-3, gelsolin, cathepsin K, and macrophage scavenger receptor types I and II should be emphasized.

**Figure 2.** Search strategy flowchart. From the 571 abstracts collected in PubMed, using the keywords “epicardial adipose tissue AND coronary artery disease”, 44 reports were used for the systematic review and 527 were excluded, according to the criteria above mentioned. CAD, coronary artery disease; EAT, epicardial adipose tissue.
Figure 3. The workflow for proteins/genes analysis using bioinformatic tools. SAT, subcutaneous adipose tissue.

Figure 4. Venn diagram representing the distribution of identified proteins per control evidencing the overlapped and unique proteins. Proteins identified in EAT from studies using EAT non-coronary artery disease (non-CAD) as control (A) and corresponding altered biological processes (C); Proteins identified in EAT from studies using SAT CAD as control (B) and corresponding altered biological processes (D).
Figure 5. Venn diagram representing the distribution of proteins per control evidencing the overlapped and unique proteins in EAT, using the protein up- and downregulated in EAT CAD as compared with EAT non-CAD and SAT CAD.

Table 1. List of upregulated and downregulated proteins selected to characterize EAT. The putative secreted proteins are identified in bold.

| Upregulated Subgroup                  | Downregulated Subgroup                  |
|---------------------------------------|-----------------------------------------|
| (27 Proteins, 18 Secreted Proteins)   | (19 Proteins, 8 Secreted Proteins)      |
| **Tumor necrosis factor**             | **Tyrosine-protein kinase ABL2**        |
| Mitogen-activated protein kinase kinase 8 | 5-aminolevulinate synthase              |
| Scavenger receptor cysteine-rich type 1 protein M130 |                                |
| C-C motif chemokine 2                 | erythroid-specific, mitochondrial       |
| C-C chemokine receptor type 2         | Amphiplysin                             |
| Arachidonate 5-lipxygenase-activating protein |                                |
| C-C motif chemokine 5                 | Aminopeptidase N                        |
| Nitric oxide synthase, endothelial    |                                         |
| Neutrophil cytosol factor 2           | Cathepsin K                            |
| Histone-lysine N-methyltransferase PRDM16 |                                    |
| C-C motif chemokine 18                | Dynamin-1                              |
| Cathespin E                           | Gelsolin                               |
| Leucine-rich repeat transmembrane protein FLRT3 |                                |
| Interleukin-7 receptor subunit alpha  | Macrophage scavenger receptor types I and II |
|                                         | Ubiquitin carboxyl-terminal hydrolase isozyme L1 |
| C-C motif chemokine 13                | Butyrophilin-like protein 9            |
| T-cell surface glycoprotein CD3 zeta chain | Zinc finger and BTB domain-containing protein 16 |
| HLA class I histocompatibility antigen protein P5 |                                |
| Toll-like receptor 2                  | Galectin-3                             |
| Interleukin-18                         | Secreted frizzled-related protein 2     |
| E3 SUMO-protein ligase EGR2            | Hormone-sensitive lipase               |
| Early activation antigen CD69         | Prelamin-A/C                           |
| L-selectin                            |                                         |
| Alpha-1-antichymotrypsin              | Actin, gamma-enteric smooth muscle     |
| Complement C3                         | Collagen alpha-1(I) chain              |
| Coronin-1A                            |                                         |
| Intercellular adhesion molecule 3     | Acyl-CoA-binding protein                |
| Integrin beta-2                       | Fructose-bisphosphate aldolase C       |
4. Bioinformatics Analysis Provides a Protein Network Overview from CAD Epicardial Adipose Tissue

4.1. Functional Protein Categorization and Integrative Analysis with REACTOME

To further understand the biological implications of EAT in CAD condition, we performed network enrichment analysis using Reactome. The data revealed that upregulated proteins were integrated into 59 pathways and downregulated proteins were integrated into 47 pathways, with a \( p \) value restricted to \( \leq 0.05 \).

The most representative pathways for the upregulated subgroup of proteins were interleukin-10 signaling \( (p = 8.66 \times 10^{-8}) \), signaling by interleukins \( (p = 8.91 \times 10^{-7}) \), immune system \( (p = 9.07 \times 10^{-7}) \), chemokine receptors bind chemokines \( (p = 1.15 \times 10^{-5}) \), and innate immune system \( (p = 6.06 \times 10^{-5}, \) Table 2). The most representative pathways for the downregulated subgroup of proteins were depolymerization of the nuclear \( (p = 4.05 \times 10^{-4}) \), scavenging by class A receptors \( (p = 5.7 \times 10^{-4}) \), initiation of nuclear envelope reformation \( (p = 6.3 \times 10^{-4}) \), apoptotic cleavage of cellular proteins \( (p = 2.23 \times 10^{-3}) \), and apoptotic execution phase \( (p = 4.11 \times 10^{-3}, \) Table 2).

4.2. Predictions of Putative Secreted Proteins

In order to add new insights regarding EAT and CAD crosstalk, SignalP and SecretomeP bioinformatics analysis of the upregulated and downregulated subgroups of proteins retrieved which proteins were putatively secreted (Table S5). These proteins are highlighted in bold in Table 1 and were reanalyzed with Reactome, showing similar results to those presented in Table 2. Briefly, upregulated secreted proteins were integrated into 47 pathways and downregulated secreted proteins were integrated into 39 pathways, with a \( p \) value restricted to \( \leq 0.05 \). The most prevalent pathways associated with upregulated secreted proteins were interleukin-10 signaling \( (p = 8.91 \times 10^{-7}) \), signaling by interleukins \( (p = 5.33 \times 10^{-6}) \), immune system \( (p = 1.14 \times 10^{-5}) \), interleukin-4 and interleukin-13 signaling \( (p = 3.08 \times 10^{-5}) \), and interleukin-18 signaling \( (p = 1.05 \times 10^{-4}, \) Table 3). In contrast, the most prevalent pathways associated with downregulated secreted proteins were binding and uptake of ligands by scavenger receptors \( (p = 7.75 \times 10^{-5}) \), RUNX2 regulates genes involved in differentiation of myeloid cells \( (p = 8.6 \times 10^{-4}) \), neutrophil degranulation \( (p = 3.01 \times 10^{-4}) \), degradation of the extracellular matrix (ECM) \( (p = 3.41 \times 10^{-3}) \), and RUNX1 regulates transcription of genes involved in differentiation of myeloid cells \( (p = 3.5 \times 10^{-3}) \).
Table 2. The 10 most relevant pathways sorted by p value using the upregulated and downregulated subgroups of proteins. Entities found in each pathway are described in Table S4.

| Pathway Name                          | Entities Found | Entities Total | Entities Ratio | Entities p Value | Entities FDR |
|---------------------------------------|----------------|----------------|----------------|------------------|--------------|
| **Upregulated Proteins**              |                |                |                |                  |              |
| Interleukin-10 signaling               | 5              | 45             | 0.004          | $8.66 \times 10^{-8}$ | $1.69 \times 10^{-5}$ |
| Signaling by Interleukins              | 9              | 456            | 0.04           | $8.91 \times 10^{-7}$ | $5.9 \times 10^{-5}$  |
| Immune System                         | 18             | 2398           | 0.21           | $9.07 \times 10^{-7}$ | $5.9 \times 10^{-5}$  |
| Chemokine receptors bind chemokines    | 4              | 57             | 0.005          | $1.15 \times 10^{-5}$ | $5.54 \times 10^{-4}$ |
| Innate Immune System                  | 11             | 1187           | 0.104          | $6.06 \times 10^{-5}$ | $2.36 \times 10^{-3}$ |
| Peptide ligand-binding receptors      | 5              | 198            | 0.017          | $1.1 \times 10^{-4}$ | $3.53 \times 10^{-3}$ |
| Interleukin-4 and Interleukin-13 signaling | 4       | 111            | 0.01           | $1.52 \times 10^{-4}$ | $4.09 \times 10^{-3}$ |
| Interleukin-18 signaling              | 2              | 9              | 0.001          | $2.32 \times 10^{-4}$ | $5.56 \times 10^{-3}$ |
| Adaptive Immune System                | 9              | 944            | 0.083          | $2.9 \times 10^{-4}$ | $6.09 \times 10^{-3}$ |
| Cytokine Signaling in Immune system   | 9              | 981            | 0.086          | $3.86 \times 10^{-4}$ | $7.34 \times 10^{-3}$ |
| **Downregulated Proteins**            |                |                |                |                  |              |
| Depolymerisation of the Nuclear       | 2              | 16             | 0.001          | $4.05 \times 10^{-4}$ | $2.65 \times 10^{-2}$ |
| Scavenging by Class A Receptors       | 2              | 19             | 0.002          | $5.7 \times 10^{-4}$ | $2.65 \times 10^{-2}$ |
| Initiation of Nuclear Envelope (NE) Reformation | 2  | 20             | 0.002          | $6.3 \times 10^{-4}$ | $2.65 \times 10^{-2}$ |
| Apoptotic cleavage of cellular proteins | 2        | 38             | 0.003          | $2.23 \times 10^{-3}$ | $6.91 \times 10^{-2}$ |
| Apoptotic execution phase             | 2              | 52             | 0.005          | $4.11 \times 10^{-3}$ | $8.17 \times 10^{-2}$ |
| Nuclear Envelope Breakdown            | 2              | 58             | 0.005          | $5.08 \times 10^{-3}$ | $8.17 \times 10^{-2}$ |
| Breakdown of the nuclear lamina       | 1              | 3              | 0              | $5.5 \times 10^{-3}$ | $8.17 \times 10^{-2}$ |
| Collagen degradation                  | 2              | 64             | 0.006          | $6.14 \times 10^{-3}$ | $8.17 \times 10^{-2}$ |
| Nuclear Envelope (NE) Reassembly     | 2              | 78             | 0.007          | $8.99 \times 10^{-3}$ | $8.17 \times 10^{-2}$ |
| RUNX2 regulates genes involved in differentiation of myeloid cells | 1 | 5 | 0 | $9.15 \times 10^{-3}$ | $8.17 \times 10^{-2}$ |

Entities reflect proteins, small molecules and genes regarding the pathway. Entities p value indicates that the proteins within this pathway represent more than would be expected if the set were random, corrected for multiple testing (Benjamini–Hochberg) that arises from evaluation of the submitted list of identifiers against every pathway. FDR indicates false discovery rate corrected for the probability of over-representation.
Table 3. The 10 most relevant pathways sorted by $p$ value using upregulated and downregulated proteins predicted to be secreted. Entities found in each pathway are described in Table S6.

| Pathway Name                                      | Entities Found | Entities Total | Entities Ratio | Entities $p$ Value | Entities FDR  |
|---------------------------------------------------|----------------|----------------|----------------|-------------------|--------------|
| **Upregulated Proteins**                          |                |                |                |                   |              |
| Interleukin-10 signaling                          | 4              | 45             | 0.004          | $8.91 \times 10^{-7}$ | $1.08 \times 10^{-4}$ |
| Signaling by Interleukins                         | 7              | 456            | 0.04           | $5.33 \times 10^{-6}$ | $3.2 \times 10^{-4}$ |
| Immune System                                     | 13             | 2398           | 0.21           | $1.14 \times 10^{-5}$ | $4.58 \times 10^{-4}$ |
| Interleukin-4 and Interleukin-13 signaling        | 4              | 111            | 0.01           | $3.08 \times 10^{-5}$ | $9.23 \times 10^{-4}$ |
| Interleukin-18 signaling                         | 2              | 9              | 0.001          | $1.05 \times 10^{-4}$ | $2.27 \times 10^{-3}$ |
| Chemokine receptors bind chemokines                | 3              | 57             | 0.005          | $1.15 \times 10^{-4}$ | $2.27 \times 10^{-3}$ |
| Peptide ligand-binding receptors                   | 4              | 198            | 0.017          | $2.84 \times 10^{-4}$ | $4.83 \times 10^{-3}$ |
| Cytokine Signaling in Immune system                | 7              | 981            | 0.086          | $6.86 \times 10^{-4}$ | $9.59 \times 10^{-3}$ |
| Purinergic signaling in Leishmaniasis infection    | 2              | 25             | 0.002          | $8.00 \times 10^{-4}$ | $9.59 \times 10^{-3}$ |
| Cell recruitment (proinflammatory response)       | 2              | 25             | 0.002          | $8.00 \times 10^{-4}$ | $9.59 \times 10^{-3}$ |
| **Downregulated Proteins**                        |                |                |                |                   |              |
| Binding and Uptake of Ligands by Scavenger Receptors | 2              | 19             | 0.002          | $7.7 \times 10^{-5}$ | $4.85 \times 10^{-3}$ |
| RUNX2 regulates genes involved in differentiation of myeloid cells | 2              | 64             | 0.006          | $8.6 \times 10^{-4}$ | $2.58 \times 10^{-2}$ |
| Neutrophil degranulation                          | 2              | 121            | 0.011          | $3.01 \times 10^{-4}$ | $2.58 \times 10^{-2}$ |
| Degradation of the extracellular matrix            | 2              | 129            | 0.011          | $3.41 \times 10^{-3}$ | $2.58 \times 10^{-2}$ |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | 1              | 5              | 0              | $3.5 \times 10^{-3}$ | $2.58 \times 10^{-2}$ |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | 3              | 480            | 0.042          | $3.55 \times 10^{-3}$ | $2.58 \times 10^{-2}$ |
| Innate Immune System                              | 2              | 140            | 0.012          | $4.01 \times 10^{-3}$ | $2.58 \times 10^{-2}$ |
| GPIb-IX-V activation signalling                   | 1              | 8              | 0.001          | $5.59 \times 10^{-3}$ | $2.58 \times 10^{-2}$ |
| Caspase-mediated cleavage of cytoskeletal proteins | 1              | 8              | 0.001          | $5.59 \times 10^{-3}$ | $2.58 \times 10^{-2}$ |
| Transcriptional regulation by RUNX1               | 4              | 1187           | 0.104          | $5.79 \times 10^{-3}$ | $2.58 \times 10^{-2}$ |

Entities reflect proteins, small molecules and genes regarding the pathway. Entities $p$ value indicates that the proteins within this pathway represent more than would be expected if the set were random, corrected for multiple testing (Benjamini–Hochberg) that arises from evaluation of the submitted list of identifiers against every pathway. FDR indicates false discovery rate corrected for the probability of over-representation.
5. Discussion

This study was the first to compile dysregulated proteins/genes from different studies to scrutinize the potential role of EAT in CAD. Despite the significant amount of research focusing on the impact of EAT on CAD, controversial results still preclude a clear vision of this interaction. This partially results from the fact that some studies have different control groups, while other studies describe different proteins, even if related to the same biological processes. Lastly, some proteins are inconsistently regulated, i.e., being upregulated or downregulated, depending on the study (Figure 5). This inconsistency proves that the same protein can behave differently depending on other comorbidities that cannot be excluded from human studies. With this systematic review, we were able to highlight a group of proteins that were consistently regulated among all studies, accounting for the control used in each study (EAT CAD vs. EAT non-CAD or EAT CAD vs. SAT CAD). The analysis of these proteins revealed the main pathways altered in the EAT and how they could communicate with the heart, potentially contributing to CAD development.

5.1. The Contribution of Epicardial Adipose Tissue to the Proinflammatory Profile of CAD

The bioinformatic analysis, presented in this study, revealed innate and adaptive immunity activation as the most relevant signaling pathways in EAT from CAD patients. Accordingly, it is currently accepted that the adipose tissue represents an important and highly active part of the immune system [24]. Adipose tissue is composed of two distinct entities, i.e., adipocytes and the stromal-vascular fraction formed by ECM with dispersed fibroblasts, preadipocytes, endothelial and immune cells [25]. Adipose tissue-resident immune cells include almost the full spectrum of immune cell types, namely macrophages, B cells, T cells, neutrophils, eosinophils, and mast cells [24]. Cytokines and chemokines are released from a wide range of immune cells, as confirmed by our analysis (Tables 1 and 2). These factors are indispensable for the communication between immune and non-immune cells and for the coordination of inflammatory responses, as well as the crosstalk between innate and adaptive immune system [26]. The chemokines overexpression, such as CCL2, CCL5, CCL13 and CCL18, triggers the recruitment of immune cells and the macrophages migration (Table 1). Macrophages plasticity endows their diverse activities in response to various environmental stimuli [27]. The M1 macrophages stimulate the conversion of unpolarized macrophages to M1 through the release of various proinflammatory and proatherogenic cytokines (IL-6 and TNF-α) and chemokines. For example, TNF-α initiates and amplifies inflammatory cascades through immune cells recruitment, chemokine regulation, and cytokine release, as well as the migration and mitogenesis of vascular smooth muscle and endothelial cells. Indeed, increased levels of TNF-α have been reported in EAT from CAD patients [28] (Table 1). Inversely, M2 macrophages can be activated by cytokines IL-4/IL-13, secreted from various cells in adipose tissue and are crucial to the promotion of preadipocyte survival, wound healing, and control of inflammation via anti-inflammatory cytokines production, such as IL-10, as evident in Table 2. Several studies have reported the influx of macrophages into the epicardial fat and have correlated the ratio of M1/M2 macrophages with the severity of CAD [29]. Indeed, excessive inflammation in CAD results from an imbalance between these two pathways, favoring M1 polarization and proinflammatory environment. Furthermore, other inflammatory pathways have been observed, such as IL-18 signaling, capable of increasing the atherosclerotic lesion size by T-lymphocytes attraction. Activated immune cells secrete several cytokines that influence adipocyte function and its paracrine secretion of cytokines (adipocytokines). Simultaneously, adipocytes produce inflammatory adipocytokines and ECM proteins, supporting infiltration and activation of immune cells. This vicious cycle creates an optimal microenvironment for low-grade inflammation, which underlies adipose tissue dysfunction.

Many studies have reported that CAD progression was closely associated with a higher volume of EAT, independently of obesity. Inflammation promotes adipose tissue expansion either through hypertrophy of existing adipocytes or differentiation of new adipocytes from adipogenic precursor cells (hyperplasia or adipogenesis) [30]. For instance, Sadler et al. showed that low-dose LPS led to
adipocyte hyperplasia at the site of administration, associated with a net loss of adipose tissue collagen (Table 2), evidenced that the ability to effectively degrade ECM was essential for adipose tissue expansion [31,32]. In parallel to ECM remodeling, proinflammatory stimuli also promote angiogenesis in adipose tissue. These processes are both essential for adipogenesis in vivo [32] and explain the increased fat volume described in several studies [33]. Moreover, adipocytes hypertrophy is also associated with higher expression of proinflammatory adipocytokines, further perpetuating the vicious cycle of inflammation and fat expansion.

5.2. The Contribution of Epicardial Adipose Tissue to the Atherosclerotic Plaque Formation in CAD

Inflammation is also considered to be a central driver of atherogenesis and of the development of vulnerable atherosclerotic plaques [34,35]. Indeed, the proatherogenic effects of adipose tissue immune cells are carried out in the endocrine and paracrine manner by increased levels of the putative secreted proinflammatory proteins, as described above. Interestingly, we found IL-4, IL-10, and IL-13 signaling to be increased. We trust that the upregulation of these anti-inflammatory pathways might represent a compensatory mechanism to promote M2 polarization and to inhibit many cellular processes underlying plaque progression, rupture, or thrombosis, which include nuclear factor-κB activation, metalloproteinase proteinase production, tissue factor expression, and cell death. Further reinforcing this idea, other studies have shown that these factors were essential to keep the balance of the inflammatory response, to promote tissue repair, and to ensure plaque stability [36,37]. Interestingly, our analysis revealed reduced expression of cathepsin K and galectin-3 proteins, which have both been linked to the progression of atherosclerotic plaque. While cathepsin K has been associated with progression of unstable plaques and closely associated with CAD [38], galectin-3 has been shown to contribute to macrophage differentiation, foam cell formation, endothelial dysfunction, and vascular smooth muscle cells proliferation and migration [39] in the atheroma and its inhibition might reduce plaque progression [40]. Moreover, galectin-3 deficiency, in a mice model of atherosclerosis (ApoE−/−), decreased plaque size, its necrotic core, and collagen content [40], which was consistent with our findings (Table 1). The presence of collagen in the fibrous atherosclerotic plaque cap is essential to maintain its stability, avoiding plaque rupture [41]. In addition, we found the macrophage scavenger receptor class A and the transcript factor RUNX2 to be downregulated in EAT. Macrophage scavenger receptor class A is known to be involved in foam cell development, mediating the influx of lipids into the macrophages [42], and therefore knockout mice for this gene have shown lower proinflammatory responses, macrophage apoptosis, and cellular necrosis with better stabilization of atherosclerotic plaques [43].

Similarly, RUNX2 is activated by atherogenic factors such as lipid-derived products from oxidation present in valve lesions that can promote calcification and is increased in advanced calcified lesions, supporting their implication in active osteogenesis and mineralization of human atherosclerotic coronary arteries [44]. Nevertheless, RUNX2 downregulation seems to be crucial to keep EAT expansion in response to inflammation, once RUNX2 upregulation restrains adipogenesis [45]. The proteome of epicardial fat likely acts as a local trigger for coronary plaque growth, calcification and stability in different stages of CAD. Accordingly, an unbalance between calcification promoters and inhibitors in epicardial fat has been reported in advanced stages of CAD [20].

5.3. The Epicardial Adipose Tissue and Atheroma Communication

Notably, the cellular composition of adipose tissue is highly plastic and can be regulated by environmental acute and chronic stimuli [24]. This suggests that the signals arising from the cardiovascular system can modulate the differentiation and function of adipocytes, and consequently adipose tissue quality. This concept supports a bidirectional crosstalk between epicardial fat and the coronary arteries, as represented in Figure 6. Antonopoulos et al., described an increased expression of adiponectin in perivascular adipose tissue in response to the activation of NADPH oxidase in the human arterial wall using an ex vivo model of human internal mammary arteries and perivascular
adipose tissue co-cultures [46]. Moreover, inflammation and alteration in adipokines expression were reported in perivascular adipose tissue of rats and pigs as a consequence of balloon-induced vascular injuries and drug-eluting stent-induced coronary vasoconstriction [47,48]. The inflammation present in atherosclerotic coronary arteries may contribute to attracting immune cells to EAT, as observed by the increased number of chemokines upregulated (Tables 1 and 2). By doing so, the atheroma may affect the EAT composition and signaling.

Figure 6. Interactions between EAT and atherosclerotic coronary arteries. In response to inflammatory cytokines released by atheroma, EAT can modulate the differentiation and function of adipocytes. EAT, located in close proximity with heart, can secrete adipocytokines which diffuse directly to the coronary arteries, promoting coronary inflammation. The figure was produced using BioRender and Servier Medical Art.

5.4. Influence of Epicardial Adipose Tissue Proteome on Cardiac Function and Structure

Beyond the influence of EAT on CAD, EAT is also directly connected to the myocardium. Inflammatory mediators have significant repercussions in all myocardial cell types, namely in cardiomyocytes, fibroblasts, and endothelial cells [49,50]. The deleterious effects of the proinflammatory cytokines include myocardial cell death, blunted β-adrenergic signaling, fetal gene reactivation, endothelial dysfunction, and collagen deposition [49], which are major determinants in the pathogenesis of cardiac disorders. There is increasing evidence that proinflammatory adipocytokines trigger cardiomyocyte hypertrophy and apoptosis, fibroblast differentiation into active myofibroblasts, and adhesion of immune cells to the endothelium and trans-endothelial migration [49,51,52]. Moreover, experimental studies have shown that inflammation was responsible for left ventricular (LV) diastolic and endothelial dysfunction and progression towards heart failure with preserved ejection fraction.
Cytokines such as TNF-α (Table 1) promote a direct negative inotropic effect, through downregulation of Ca²⁺-regulating genes including sarcoplasmic reticulum Ca²⁺ ATPase and Ca²⁺-release channel [55] and stimulate myofibroblasts activation [56,57]. Transgenic mice with cardiac-specific overexpression of TNF-α developed dilated cardiomyopathy with ventricular hypertrophy, ventricular dilatation, interstitial infiltrates, interstitial fibrosis, and reduced ejection fraction [58]. In contrast, IL-10 signaling suppressed the inflammatory response and contributed to improved LV function and remodeling (Table 2). Treatment approaches with IL-10 seem to be beneficial for preventing hypertrophy, reducing fibrosis, and preserving cardiac function, through the maintenance of cytokine homeostasis [59]. IL-4 and IL-13 signaling also modulate physiological processes, such as tissue repair, ECM remodeling, and metabolism homeostasis [60,61]. Additionally, we have observed a downregulation of RUNX1, that has been identified as a key regulator of adverse cardiac remodeling following myocardial infarction. RUNX1-deficient mice or RUNX1 knockout prevented adverse cardiac remodeling, restrained myocardial scar formation, and assured normal calcium homeostasis in cardiomyocytes [62]. Considering all the identified pathways, we believe that EAT fights to maintain cardiovascular homeostasis, orchestrating the inhibition and promotion of certain pathways.

5.5. Therapeutic Strategies against Inflammation-Related Coronary Artery Disease

Current pharmacological strategies for CAD patients include reducing angina symptoms, exercise-induced ischemia, and preventing cardiovascular events [63]. Taking into account the analysis presented in our study regarding the major impact of inflammation in CAD, therapeutic strategies should target the immune system with anti-inflammatory approaches [52]. Recently, the randomized clinical trial CANTOS assessed the effect of canakinumab, a human monoclonal antibody against IL-1β with anti-inflammatory properties. Canakinumab reduced significantly high-sensitivity C-reactive protein level from baseline in a dose-dependent fashion for three months, which persisted even after the treatment ended [64]. Moreover, the anti-inflammatory therapy targeting the IL-1β reduced the recurrence of cardiovascular events in well-treated CAD patients independent of any lowering effects on low-density lipoproteins (LDL) cholesterol levels [64].

6. Conclusions

The communication between EAT and CAD remains unclear. The dysregulated proteins, identified herein, highlight the importance of inflammatory processes for modulating the local environment and the progression of CAD. Inflammation triggers cellular and metabolic adaptations of epicardial fat that facilitate the formation and progression of atherogenesis of coronaries. Although several authors have supported that EAT thickness was a predictor for CAD, we also trust that the quality of epicardial fat should be assessed. For instance, to evaluate EAT-resident immune cells would ease the comprehension of the dynamic signaling at different time points of CAD progression.

In conclusion, future studies involving immune interventions should envisage clarifying the influence of anti-inflammatory drugs in EAT and how to modulate the paracrine and endocrine communication between epicardial fat and coronary arteries during CAD.

Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/22/8866/s1, Figure S1: Representative sketch results of enrichment analysis with Reactome, Table S1: Eligible studied included and the proteins identified, Table S2: List of proteins identified in EAT from studies using EAT non-CAD as control or SAT CAD as control, Table S3: Distribution of proteins by Venn diagram, Table S4: Entities found in the 10 most relevant pathways sorted by p value using upregulated and downregulated subgroups of proteins, Table S5: Signal P/SecretomeP report, Table S6: Entities found in the 10 most relevant pathways sorted by p value using the upregulated and downregulated subgroups of potentially secreted proteins.

Funding: This project is supported by Fundo Europeu de Desenvolvimento Regional (FEDER) through Compete 2020, Programa Operacional Competitividade E Internacionalização (POCI); the project DOCNET (norte-01-0145-feder-000003), supported by Norte Portugal regional operational programme (norte 2020), under the
Portugal 2020 partnership agreement, through the European Regional Development Fund (ERDF); the project NETDIAMOND (POCI-01-0145FEDER-016385), supported by European Structural And Investment Funds; Lisbon’s regional operational program 2020, and supported by the Cardiovascular R&D Center, financed by national funds through FCT, Fundação para a Ciência e Tecnologia, I.P., under the scope of the project UIDP/00051/2020. Glória Conceição is supported by the PhD grant program (norte-085369-FSE-000024), financed by Norte Portugal Regional Operational Programme (NORTE 2020), through the CCDRN, PORTUGAL 2020 and the European Social Fund (ESF).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Aerea, S.F.; et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384, 766–781. [CrossRef]

2. Manno, C.; Campobasso, N.; Nardecchia, A.; Triggiani, V.; Zupo, R.; Gesualdo, L.; Silvestris, F.; De Pergola, G. Relationship of para-and perirenal fat and epicardial fat with metabolic parameters in overweight and obese subjects. Eat. Weight Disord. 2019, 24, 24–67. [CrossRef] [PubMed]

3. Iacobellis, G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat. Rev. Endocrinol. 2015, 11, 363–371. [CrossRef] [PubMed]

4. Taguchi, R.; Takasu, J.; Itani, Y.; Yamamoto, R.; Yokoyama, K.; Watanabe, S.; Masuda, Y. Pericardial fat accumulation in men as a risk factor for coronary artery disease. Atherosclerosis 2001, 157, 203–209. [CrossRef]

5. Bettencourt, N.; Toschke, A.M.; Leite-Der, J.; Rocha, J.; Carvalho, M.; Sampaio, F.; Xaréu, S.; Leite-Moreira, A.; Nagel, E.; Gama, V. Epicardial adipose tissue is an independent predictor of coronary atherosclerotic burden. Int. J. Cardiol. 2012, 158, 26–32. [CrossRef] [PubMed]

6. Cassar, A.; Holmes, D.R., Jr.; Rihal, C.S.; Gersh, B.J. Chronic coronary artery disease: Diagnosis and management. Mayo Clin. Proc. 2009, 84, 1130–1146. [CrossRef] [PubMed]

7. Wolf, D.; Ley, K. Immunity and Inflammation in Atherosclerosis. Circ. Res. 2019, 124, 315–327. [CrossRef] [PubMed]

8. Ades, P.A.; Savage, P.D. Obesity in coronary heart disease: An unaddressed behavioral risk factor. Prev. Med. 2017, 104, 117–119. [CrossRef] [PubMed]

9. Piche, M.E.; Poirier, P.; Lemieux, I.; Despres, J.P. Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update. Prog. Cardiovasc. Dis. 2018, 61, 103–113. [CrossRef]

10. Libby, P.; Theroux, P. Pathophysiology of coronary artery disease. Circulation 2005, 111, 3481–3488. [CrossRef]

11. Libby, P.; Ridker, P.M.; Hansson, G.K. Leducq Transatlantic Network on A. Inflammation in atherosclerosis: From pathophysiology to practice. J. Am. Coll. Cardiol. 2009, 54, 2129–2138. [CrossRef] [PubMed]

12. Prospective Studies, C.; Whitlock, G.; Lewington, S.; Sherliker, P.; Clarke, R.; Emberson, J.; Halsey, J.; Qizilbash, N.; Collins, R.; Peto, R. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet 2009, 373, 1083–1096. [CrossRef]

13. Fuster, J.J.; Ouchi, N.; Gokce, N.; Walsh, K. Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease. Circ. Res. 2016, 118, 1786–1807. [CrossRef] [PubMed]

14. Harada, K.; Shibata, R.; Ouchi, N.; Tokuda, Y.; Funakubo, H.; Suzuki, M.; Kataoka, T.; Nagao, T.; Okumura, S.; Shinoda, N.; et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis 2016, 251, 299–304. [CrossRef] [PubMed]

15. Sicari, R.; Sironi, A.M.; Petz, R.; Frassi, F.; Chubuchny, V.; De Marchi, D.; Positano, V.; Lombardi, M.; Picano, E.; Gastaldelli, A.; et al. Pericardial rather than epicardial fat is a cardiometabolic risk marker: An MRI vs echo study. J. Am. Soc. Echocardiogr. 2011, 24, 1156–1162. [CrossRef]

16. Iacobellis, G.; Lonn, E.; Lamy, A.; Singh, N.; Sharma, A.M. Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int. J. Cardiol. 2011, 146, 452–454. [CrossRef]

17. Villasante Fricke, A.C.; Iacobellis, G. Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk. Int. J. Mol. Sci. 2019, 20, 5989. [CrossRef]

18. Bachar, G.N.; Dicker, D.; Kornowski, R.; Atar, E. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects. Am. J. Cardiol. 2012, 110, 534–538. [CrossRef]
19. Clauser, M.; Altenberger, J. Obesity and cardiac cachexia in chronic heart failure. *Herz* 2013, 38, 610–617. [CrossRef]
20. Mancio, J.; Barros, A.S.; Conceicao, G.; Pessoa-Amorim, G.; Santa, C.; Bartosch, C.; Ferreira, W.; Carvalho, M.; Ferreira, N.; Vouga, L.; et al. Epicardial adipose tissue volume and annexin A2/fetuin-A signalling are linked to coronary calcification in advanced coronary artery disease: Computed tomography and proteomic biomarkers from the EPICHEART study. *Atherosclerosis* 2020, 292, 75–83. [CrossRef]
21. Zhao, Y.X.; Zhu, H.J.; Pan, H.; Liu, X.M.; Wang, L.J.; Yang, H.B.; Li, N.; Gong, F.; Sun, W.; Zeng, Y. Comparative Proteome Analysis of Epicardial and Subcutaneous Adipose Tissues from Patients with or without Coronary Artery Disease. *Int. J. Endocrinol.* 2019, 2019, 6976712. [CrossRef] [PubMed]
22. Conceicao, G.; Matos, J.; Miranda-Silva, D.; Goncalves, N.; Sousa-Mendes, C.; Goncalves, A.; Ferreira, R.; Leite-Moreira, A.F.; Vitorino, R.; Falcao-Pires, I. Fat Quality Matters: Distinct Proteomic Signatures Between Lean and Obese Cardiac Visceral Adipose Tissue Underlie its Differential Myocardial Impact. *Cell Physiol. Biochem.* 2020, 54, 384–400. [PubMed]
23. Jassal, B.; Matthews, L.; Viteri, G.; Lorente, P.; Fabregat, A.; Sidiropoulos, K.; Cook, J.; Gillespie, M.; Haw, R.; et al. The reactome pathway knowledgebase. *Nucleic Acids Res.* 2020, 48, D498–D503. [CrossRef] [PubMed]
24. Grant, R.W.; Dixit, V.D. Adipose tissue as an immunological organ. *Obesity (Silver Spring)* 2015, 23, 512–518. [CrossRef] [PubMed]
25. Mraz, M.; Haluzik, M. The role of adipose tissue immune cells in obesity and low-grade inflammation. *J. Endocrinol.* 2014, 222, R113–R127. [CrossRef] [PubMed]
26. Lacy, P. Editorial: Secretion of cytokines and chemokines by innate immune cells. *Front. Immunol.* 2015, 6, 190. [CrossRef]
27. Wynn, T.A.; Chawla, A.; Pollard, J.W. Macrophage biology in development, homeostasis and disease. *Nature* 2013, 496, 445–455. [CrossRef]
28. Mazurek, T.; Zhang, L.; Zalewski, A.; Mannion, J.D.; Diehl, J.T.; Arafat, H.; Sarov-Blat, L.; O’Brien, S.; Keiper, E.A.; Johnson, A.G.; et al. Human epicardial adipose tissue is a source of inflammatory mediators. *Circulation* 2003, 108, 2460–2466. [CrossRef]
29. Hirata, Y.; Tabata, M.; Kurobe, H.; Motoki, T.; Akaike, M.; Nishio, C.; Higashida, M.; Mikasa, H.; Nakaya, Y.; Takanashi, S.; et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. *J. Am. Coll. Cardiol.* 2011, 58, 248–255. [CrossRef]
30. Vishvanath, L.; Gupta, R.K. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. *J. Clin. Investig.* 2019, 129, 4022–4031. [CrossRef]
31. Sadler, D.; Mattacks, C.A.; Pond, C.M. Changes in adipocytes and dendritic cells in lymph node containing adipose depots during and after many weeks of mild inflammation. *J. Anat.* 2005, 207, 769–781. [CrossRef]
32. Wernstedt Asterholm, I.; Tao, C.; Morley, T.S.; Wang, Q.A.; Delgado-Lopez, F.; Wang, Z.V.; Scherer, P.E. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. *Cell Metab.* 2014, 20, 103–118. [CrossRef] [PubMed]
33. McClain, J.; Hsu, F.; Brown, E.; Burke, G.; Carr, J.; Harris, T.; Kritchevsky, S.; Szklo, M.; Tracy, R.; Ding, J. Pericardial adipose tissue and coronary artery calcification in the Multi-ethnic Study of Atherosclerosis (MESA). *Obesity (Silver Spring)* 2013, 21, 1056–1063. [CrossRef] [PubMed]
34. Raggi, P.; Genest, J.; Giles, J.T.; Rayner, K.J.; Dwivedi, G.; Beanlands, R.S.; Gupta, M. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. *Atherosclerosis* 2018, 276, 98–108. [CrossRef]
35. Antoniades, C.; Kotanidis, C.P.; Berman, D.S. State-of-the-art review article. Atherosclerosis affecting fat: What can we learn by imaging perivascular adipose tissue? *J. Cardiovusc. Comput. Tomogr.* 2019, 13, 288–296. [CrossRef]
36. Barrett, T.J. Macrophages in Atherosclerosis Regression. *Arterioscler. Thromb. Vasc. Biol.* 2020, 40, 20–33. [CrossRef]
37. Nishihira, K.; Imamura, T.; Yamashita, A.; Hatakeyama, K.; Shibata, Y.; Nagatomo, Y.; Date, H.; Kita, T.; Eto, T.; Asada, Y. Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy. *Eur. Heart J.* 2006, 27, 1685–1689. [CrossRef]
38. Zhao, H.; Qin, X.; Wang, S.; Sun, X.; Dong, B. Decreased cathepsin K levels in human atherosclerotic plaques are associated with plaque instability. *Exp. Ther. Med.* 2017, 14, 3471–3476. [CrossRef]
39. Gao, Z.; Liu, Z.; Wang, R.; Zheng, Y.; Li, H.; Yang, L. Galectin-3 is a Potential Mediator for Atherosclerosis. *J. Immunol. Res.* 2020, 2020, 5284728. [CrossRef]

40. MacKinnon, A.C.; Liu, X.; Hadoke, P.W.; Miller, M.R.; Newby, D.E.; Sethi, T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. *Glycobiology* 2013, 23, 654–663. [CrossRef]

41. Hansson, G.K.; Libby, P.; Tabas, I. Inflammation and plaque vulnerability. *J. Intern Med.* 2015, 278, 483–493. [CrossRef][PubMed]

42. de Winther, M.P.; van Dijk, K.W.; Havekes, L.M.; Hofker, M.H. Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 2000, 20, 290–297. [CrossRef]

43. Zani, I.A.; Stephen, S.L.; Mughal, N.A.; Russell, D.; Homer-Vanniasinkam, S.; Wheatcroft, S.B.; Ponnambalam, S. Scavenger receptor structure and function in health and disease. *Cells* 2015, 4, 178–201. [CrossRef][PubMed]

44. Alexopoulos, A.; Peroukides, S.; Bravou, V.; Pyrgakis, V.; Papadaki, H. Implication of bone regulatory factors in human coronary artery calcification. *Artery Res.* 2011, 5, 108. [CrossRef]

45. Zhang, Y.Y.; Li, X.; Qian, S.W.; Guo, L.; Huang, H.Y.; He, Q.; Liu, Y.; Ma, C.-G.; Tang, Q.-Q. Down-regulation of type I Runx2 mediated by dexamethasone is required for 3T3-L1 adipogenesis. *Mol. Endocrinol.* 2012, 26, 798–808. [CrossRef][PubMed]

46. Antonopoulos, A.S.; Margaritis, M.; Coutinho, P.; Shirodaria, C.; Psarros, C.; Herdman, L.; Sanna, F.; De Silva, R.; Petrou, M.; Sayeed, R.; et al. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: The regulatory role of perivascular adipose tissue. *Diabetes* 2015, 64, 2207–2219. [CrossRef][PubMed]

47. Takaoka, M.; Suzuki, H.; Shioda, S.; Sekikawa, K.; Saito, Y.; Nagai, R.; Sata, M. Endovascular injury induces rapid phenotypic changes in perivascular adipose tissue. *Arterioscler. Thromb. Vasc. Biol.* 2010, 30, 1576–1582. [CrossRef]

48. Ohyama, K.; Matsumoto, Y.; Amamizu, H.; Uzuka, H.; Nishimiya, K.; Morosawa, S.; Hirano, M.; Watabe, H.; Funaki, Y.; Miyata, S.; et al. Association of Coronary Perivascular Adipose Tissue Inflammation and Drug-Eluting Stent-Induced Coronary Hypercontracting Responses in Pigs: (18)F-Fluorodeoxyglucose Positron Emission Tomography Imaging Study. *Arterioscler. Thromb. Vasc. Biol.* 2017, 37, 1757–1764. [CrossRef]

49. Van Linthout, S.; Tschope, C. Inflammation-Cause or Consequence of Heart Failure or Both? *Curr. Heart Fail Rep.* 2017, 14, 251–265. [CrossRef]

50. Northcott, J.M.; Yeganeh, A.; Taylor, C.G.; Zahradka, P.; Wigle, J.T. Adipokines and the cardiovascular system: Mechanisms mediating health and disease. *Can. J. Physiol. Pharmacol.* 2012, 90, 1029–1059. [CrossRef]

51. Van Linthout, S.; Miteva, K.; Tschope, C. Crosstalk between fibroblasts and inflammatory cells. *Cardiovasc. Res.* 2014, 102, 258–269. [CrossRef][PubMed]

52. Frantz, S.; Falcao-Pires, I.; Balligand, J.L.; Bauersachs, J.; Brutsaert, D.; Ciccarelli, M.; Dawson, D.; De Windt, L.J.; Giacca, M.; Hamdani, N.; et al. The innate immune system in chronic cardiomyopathy: A European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. *Eur. J. Heart Fail.* 2018, 20, 445–459. [CrossRef][PubMed]

53. Waddingham, M.T.; Sonobe, T.; Tsuchimochi, H.; Edgley, A.J.; Sukumaran, V.; Chen, Y.C.; Hansra, S.S.; Schwenke, D.O.; Umetani, K.; Aoyama, K.; et al. Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model. *J. Mol. Cell. Cardiol.* 2019, 137, 119–131. [CrossRef][PubMed]

54. Franssen, C.; Chen, S.; Unger, A.; Korkmaz, H.I.; De Keulenaer, G.W.; Tschope, C.; Leite-Moreira, A.F.; Musters, R.J.P.; Niessen, H.W.; Linke, W.A.; et al. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail* 2016, 4, 312–324. [CrossRef][PubMed]

55. Tsai, C.T.; Wu, C.K.; Lee, J.K.; Chang, S.N.; Kuo, Y.M.; Wang, Y.C.; Lai, L.-P.; Chiang, F.-T.; Hwang, J.-J.; Lin, J.-L.; et al. TNF-alpha down-regulates sarcoplasmic reticulum Ca(2)(+) ATPase expression and leads to left ventricular diastolic dysfunction through binding of NF-kappaB to promoter response element. *Cardiovasc. Res.* 2015, 105, 318–329. [CrossRef][PubMed]

56. Gurantz, D.; Cowling, R.T.; Variki, N.; Frikovskiy, E.; Moore, C.D.; Greenberg, B.H. IL-1beta and TNF-alpha upregulate angiotensin II type I (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. *J. Mol. Cell. Cardiol.* 2005, 38, 505–515. [CrossRef][PubMed]
57. Lindner, D.; Zietsch, C.; Tank, J.; Sossalla, S.; Fluschnik, N.; Hinrichs, S.; Maier, L.; Poller, W.; Blankenberg, S.; Schultheiss, H.-P.; et al. Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res. Cardiol. 2014, 109, 428. [CrossRef]

58. Kubota, T.; McTiernan, C.F.; Frye, C.S.; Slawson, S.E.; Lemster, B.H.; Koretsky, A.P.; Demetris, A.J.; Feldman, A.M. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 1997, 81, 627–635. [CrossRef]

59. Zimmer, A.; Bagchi, A.K.; Vinayak, K.; Bello-Klein, A.; Singal, P.K. Innate immune response in the pathogenesis of heart failure in survivors of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2019, 316, H435–H45. [CrossRef]

60. Ramos, G.; Frantz, S. Myocardial Metabolism Under Control of a Cytokine Receptor. J. Am. Heart Assoc. 2017, 6, e006291. [CrossRef]

61. Wodsedalek, D.J.; Paddock, S.J.; Wan, T.C.; Auchampach, J.A.; Kenarsary, A.; Tsaih, S.W.; Flister, M.J.; O’Meara, C.C. IL-13 promotes in vivo neonatal cardiomyocyte cell cycle activity and heart regeneration. Am. J. Physiol. Heart Circ. Physiol. 2019, 316, H24–H34. [CrossRef] [PubMed]

62. Riddell, A.; McBride, M.; Braun, T.; Nicklin, S.A.; Cameron, E.; Loughrey, C.M.; Martin, T.P. RUNX1: An emerging therapeutic target for cardiovascular disease. Cardiovasc. Res. 2020, 116, 1410–1423. [CrossRef] [PubMed]

63. Knuuti, J.; Wijns, W.; Saraste, A.; Capodanno, D.; Barbato, E.; Funck-Brentano, C.; Prescott, E.; Storey, R.F.; Deaton, C.; Cuisset, T.; et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020, 41, 407–477. [CrossRef] [PubMed]

64. Lorenzatti, A.; Servato, M.L. Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Eur. Cardiol. 2018, 13, 38–41. [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).